

Special Issue

Insulin-Like Growth Factors and Their Receptors on the Road to Personalized Medicine in Cancer: Fact or Fiction?

Message from the Guest Editor

Currently it is well established that IGF-1R is crucial in many physiological processes like growth, differentiation and aging, as well as it being an important player in disease development. IGF-1R is commonly expressed in human cancers and many cell lines are mitogenically responsive to physiological concentrations of IGFs. IGF-1R is classified as a RTK and accordingly tyrosine phosphorylation was considered to be the central process governing IGF-1R signalling. As such, most anti-IGF-1r strategies are designed to prevent kinase activation. The clinical success of nearly all tyrosine-kinase inhibitors is predicted by the presence of activating mutations or substantial receptor overexpression, but neither is the case with IGF-1R. IGF-1R does not show intrinsic receptor abnormalities, therefore other pathways and quantitative changes are being assessed. This Special Issue of *Cells* will follow the development of our understanding of the IGF-1R biology, the contradictions to the classical IGF-1R paradigms as well as the design of anti-IGF-1R therapeutics with a particular focus on those relating to cancer.

Guest Editor

Dr. Leonard Girnita

1. Department of Oncology-Pathology, Cellular and Molecular Tumor Pathology, Karolinska Institute, 17164 Stockholm, Sweden
2. Karolinska University Hospital, Solna, Sweden

Deadline for manuscript submissions

closed (31 January 2022)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 11.4
Indexed in PubMed



mdpi.com/si/39343

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 11.4
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).